Cyberonics' (CYBX) Revenue Growth Evaporates Amid NeuroPace, Preapproval Delays; BTIG Affirms at 'Neutral'
Tweet Send to a Friend
BTIG affirms Cyberonics (Nasdaq: CYBX) with a Neutral rating following the company's Q1 report on Thursday night.Analyst Sean Lavin noted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
